156 related articles for article (PubMed ID: 10378391)
1. Efficacy and safety of acarbose in patients with cystic fibrosis and impaired glucose tolerance.
Kentrup H; Bongers H; Spengler M; Kusenbach G; Skopnik H
Eur J Pediatr; 1999 Jun; 158(6):455-9. PubMed ID: 10378391
[TBL] [Abstract][Full Text] [Related]
2. Effects of beano on the tolerability and pharmacodynamics of acarbose.
Lettieri JT; Dain B
Clin Ther; 1998; 20(3):497-504. PubMed ID: 9663365
[TBL] [Abstract][Full Text] [Related]
3. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL; Josse RG; Leiter LA; Mihic M; Nathan DM; Palmason C; Cohen RM; Wolever TM
Diabetes Care; 1996 Nov; 19(11):1190-3. PubMed ID: 8908378
[TBL] [Abstract][Full Text] [Related]
4. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
5. The use of acarbose in the prevention and treatment of hypoglycaemia.
Lefebvre PJ; Scheen AJ
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():40-4. PubMed ID: 8001627
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
Coniff RF; Shapiro JA; Seaton TB
Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
[TBL] [Abstract][Full Text] [Related]
7. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial.
Geyer MC; Sullivan T; Tai A; Morton JM; Edwards S; Martin AJ; Perano SJ; Gagliardi L; Rayner CK; Horowitz M; Couper JJ
Diabetes Obes Metab; 2019 Mar; 21(3):700-704. PubMed ID: 30259623
[TBL] [Abstract][Full Text] [Related]
8. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with acarbose: results of a Canadian multicentre study.
Rodger NW; Chiasson JL; Josse RG; Hunt JA; Palmason C; Ross SA; Ryan EA; Tan MH; Wolever TM
Clin Invest Med; 1995 Aug; 18(4):318-24. PubMed ID: 8549019
[TBL] [Abstract][Full Text] [Related]
12. Acarbose: an alpha-glucosidase inhibitor.
Martin AE; Montgomery PA
Am J Health Syst Pharm; 1996 Oct; 53(19):2277-90; quiz 2336-7. PubMed ID: 8893066
[TBL] [Abstract][Full Text] [Related]
13. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
Dimitriadis GD; Tessari P; Go VL; Gerich JE
Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
[TBL] [Abstract][Full Text] [Related]
14. A review of the safety and efficacy of acarbose in diabetes mellitus.
Yee HS; Fong NT
Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
[TBL] [Abstract][Full Text] [Related]
15. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man.
Scheen AJ; de Magalhaes AC; Salvatore T; Lefebvre PJ
Eur J Clin Invest; 1994 Aug; 24 Suppl 3():50-4. PubMed ID: 7818725
[TBL] [Abstract][Full Text] [Related]
16. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
17. [The use of the alpha-glucosidase inhibitor acarbose for the treatment of type-2 diabetes mellitus in secondary sulfanilamide resistance].
Gendeleka GF
Lik Sprava; 1997; (6):105-7. PubMed ID: 9589946
[TBL] [Abstract][Full Text] [Related]
18. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
[TBL] [Abstract][Full Text] [Related]
19. Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated Type 1 diabetic subjects.
Rabasa-Lhoret R; Burelle Y; Ducros F; Bourque J; Lavoie C; Massicotte D; Péronnet F; Chiasson JL
Diabet Med; 2001 Sep; 18(9):739-44. PubMed ID: 11606172
[TBL] [Abstract][Full Text] [Related]
20. Peptide YY in diabetics treated chronically with an intestinal glucosidase inhibitor.
Füessl HS; Adrian TE; Uttenthal LO; Bloom SR
Klin Wochenschr; 1988 Oct; 66(19):985-9. PubMed ID: 3054280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
